Diabetes
Conference Coverage
Time to screen for liver disease in type 2 diabetes?
Questions remain on whether or not liver surveillance should be routine in people with type 2 diabetes.
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
British protocol allows insulin-treated pilots to fly safely
In a large study of commercial and private pilots with diabetes who followed strict rules, 98% of glucose levels were in target range and no pilot...
Guidelines
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
Pearl of the Month
Geriatric patients: My three rules for them
“Keeping moving” is probably the most important thing a patient can do for their health.
Conference Coverage
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
Conference Coverage
Exercise cuts diabetes death risk by a third in two studies
Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
Added analyses from ertugliflozin’s cardiovascular outcome trial hint at SGLT2 inhibitor–consistent benefits, but proven benefits remain scant.
Conference Coverage
No prior use of insulin predicts postsurgical diabetes remission
No insulin use before bariatric surgery was associated with sustained diabetes remission 10 years later in patients with type 2 diabetes.
Conference Coverage
Address root causes to manage NASH
Treat underlying factors such as obesity and diabetes to reduce risk of liver disease progression.